自动化骨扫描指数作为转移性去势抵抗性前列腺癌总生存预后影像生物标志物的3期评估
本研究为10TASQ10随机临床试验的前瞻性计划分析,评估自动化骨扫描指数(aBSI)在转移性去势抵抗性前列腺癌(mCRPC)男性中的独立预后价值。共721例可评估患者,基线aBSI与总生存显著相关(HR 1.20,95%CI 1.14-1.26,P<.001),且判别能力优于手动病灶计数(C指数0.63 vs 0.60,P=.03)。aBSI亦与症状进展时间和阿片类药物使用时间独立相关。
要点
- 基线aBSI是mCRPC患者总生存的独立预后因素。
- aBSI对总生存的判别能力优于手动病灶计数。
- aBSI越高,症状进展和需阿片类止痛的风险越高。
核心结论
- aBSI是mCRPC患者生存的独立预后影像生物标志物。
- 数据支持aBSI作为客观影像标志物用于临床试验设计和入组资格。
研究设计与样本
- 研究为3期多中心随机双盲安慰剂对照试验(10TASQ10)的前瞻性计划分析。
- 入组初治化疗的骨转移性CRPC男性,来自37个国家241个中心,2011年3月至2015年8月。
- 共入组1245例,其中721例可评估aBSI;平均年龄70.6岁(SD 8.0,范围47-90)。
主要发现
- 基线aBSI中位数1.07(范围0-32.60),与总生存显著相关(HR 1.20,95%CI 1.14-1.26,P<.001)。
- 按aBSI四分位(从低到高)中位总生存分别为34.7、27.3、21.7和13.3个月。
- aBSI对总生存的判别能力(C指数0.63)显著高于手动病灶计数(C指数0.60)(P=.03)。
- 多变量模型中,较高aBSI仍与总生存独立相关(HR 1.06,95%CI 1.01-1.11,P=.03)。
- 较高aBSI亦与症状进展时间(HR 1.18,95%CI 1.13-1.23,P<.001)和阿片类药物使用时间(HR 1.21,95%CI 1.14-1.30,P<.001)独立相关。
临床怎么用
- aBSI可作为mCRPC患者客观的预后评估工具,辅助临床决策。
- 在临床试验设计中,aBSI可用于患者分层或入组资格判断。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Prostate cancer commonly metastasizes to bone, and bone metastases are associated with pathologic fractures, pain, and reduced survival. Bone disease is routinely visualized using the technetium Tc 99m (99mTc) bone scan; however, the standard interpretation of bone scan data relies on subjective manual assessment of counting metastatic lesion numbers. There is an unmet need for an objective and fully quantitative assessment of bone scan data. OBJECTIVE: To clinically assess in a prospectively defined analysis plan of a clinical trial the automated Bone Scan Index (aBSI) as an independent prognostic determinant of overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC). DESIGN, SETTING, AND PARTICIPANTS: This investigation was a prospectively planned analysis of the aBSI in a phase 3 multicenter randomized, double-blind, placebo-controlled clinical trial of tasquinimod (10TASQ10). Men with bone metastatic chemotherapy-naïve CRPC were recruited at 241 sites in 37 countries between March 2011 and August 2015. The statistical analysis plan to clinically evaluate the aBSI was prospectively defined and locked before unmasking of the 10TASQ10 study. The analysis of aBSI was conducted between May 25, 2016, and June 3, 2017. MAIN OUTCOMES AND MEASURES: The associations of baseline aBSI with OS, radiographic progression-free survival (rPFS), time to symptomatic progression, and time to opiate use for cancer pain. RESULTS: Of the total 1245 men enrolled, 721 were evaluable for the aBSI. The mean (SD) age (available for 719 men) was 70.6 (8.0) years (age range, 47-90 years). The aBSI population was representative of the total study population based on baseline characteristics. The aBSI (median, 1.07; range, 0-32.60) was significantly associated with OS (hazard ratio [HR], 1.20; 95% CI, 1.14-1.26; P < .001). The median OS by aBSI quartile (lowest to highest) was 34.7, 27.3, 21.7, and 13.3 months, respectively. The discriminative ability of the aBSI (C index, 0.63) in prognosticating OS was significantly higher than that of the manual lesion counting (C index, 0.60) (P = .03). In a multivariable survival model, a higher aBSI remained independently associated with OS (HR, 1.06; 95% CI, 1.01-1.11; P = .03). A higher aBSI was also independently associated with time to symptomatic progression (HR, 1.18; 95% CI, 1.13-1.23; P < .001) and time to opiate use for cancer pain (HR, 1.21; 95% CI, 1.14-1.30; P < .001). CONCLUSIONS AND RELEVANCE: To date, this investigation is the largest prospectively analyzed study to validate the aBSI as an independent prognostic imaging biomarker of survival in mCRPC. These data support the prognostic utility of the aBSI as an objective imaging biomarker in the design and eligibility of clinical trials of systemic therapies for patients with mCRPC. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01234311.
引用
- Armstrong AJ, Anand A, Edenbrandt L, et al. Phase 3 Assessment of the Automated Bone Scan Index as a Prognostic Imaging Biomarker of Overall Survival in Men With Metastatic Castration-Resistant Prostate Cancer: A Secondary Analysis of a Randomized Clinical Trial. JAMA Oncol. 2018. PMID: 29799999. doi:10.1001/jamaoncol.2018.1093
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。